Can Obama Help Vete...
Health Care: Drugs
Affymax Inc. (AFFY: NASDAQ)
$13.35 -0.79 | -5.59%
06/01/12 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 13.35 |
| 52 Week High | 16.25 |
| 52 Week Low | 3.93 |
| Avg. Daily Vol. (Mil) | 1.51 |
| Beta (3 year) | 1.94 |
| Share Related Items | |
| Mkt Cap (Mil) | 482.05 |
| Shares Out (Mil) | 36.11 |
| Float (Mil) | 31.09 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 6.90 |
| Current Ratio | 7.10 |
| LT Debt/ Equity | 0.08 |
| Total Debt / Equity | 0.09 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 5.11 |
| Price/Book | 4.29 |
| Price/Cash Flow | -26.50 |
| Per Share Data | |
| Earnings | -0.62 |
| Sales | 2.61 |
| Book Value | 3.11 |
| Cash Flow | -0.50 |
| Business Summary | |
|---|---|
| Affymax, Inc. is a biopharmaceutical company, which develops novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions. | |
| General Information | |
| 4001 Miranda Avenue
Palo Alto, CA 94304 |
|
| www.affymax.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 130 | |
| CEO: Mr. John A. Orwin | |
| Short Interest | |
| Current Month (Mil) | 4.34 |
| Previous Month (Mil) | 4.40 |
| Short Interest Ratio (Days) | 3.80 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -12.00 |
| Return on Investments | -16.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | -21.40 |
| Profit Margin | -21.60 |
Portfolios with AFFY
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- UserBurrdee
- ContributorStocks At New 52-Week Highs...
- Usersimulator
- Contributor10 Biotech Stocks on Clinic...
- UserPART 5 JPMorgan 28th Annual...
Latest AFFY Headlines from TheStreet
- 8 Stocks Rising on Monster Volume 04.02.12 | 01:04 pm
- Biotech Stock Mailbag: MAP Pharma, Affymax 03.30.12 | 05:03 am
- 8 Stocks Rising on Huge Volume 03.23.12 | 02:03 pm
- Biotech Stock Mailbag: Xoma's Big Backers, FDA Approvals Contest 03.23.12 | 05:03 am
- The Next Big Thing in Biotech: FDA Decisions
03.23.12 | 05:03 am - Biotech Stock Chat: Recap 03.15.12 | 11:03 am
- 5 Stocks Ready to Soar on Bullish Earnings 03.13.12 | 06:03 am
- More Biotech Twitter Mailbag: Orexigen, Affymax, YM Bio, Spectrum & More 02.29.12 | 07:02 am
- These Drugs Stocks Will Win FDA Approval 02.16.12 | 12:02 pm
- 6 Stocks at New 52-Week Highs 02.14.12 | 02:02 pm
Press Releases for AFFY
- Affymax To Present At The Jefferies 2012 Global Healthcare Conference - Business Wire 06.01.12 | 08:06 am
- Affymax Reports First Quarter 2012 Financial Results - Business Wire 05.07.12 | 04:05 pm
- Affymax And Takeda Announce Centers For Medicare And Medicaid Services Has Assigned A Q-Code For OMONTYS® (Peginesatide) Injection - Business Wire 04.13.12 | 08:04 am
- Affymax Receives A $50 Million Milestone Payment For U.S. Approval Of OMONTYS® (peginesatide) Injection - Business Wire 04.09.12 | 04:04 pm
- Affymax And Takeda Announce FDA Approval Of OMONTYS® (Peginesatide) Injection For The Treatment Of Anemia Due To Chronic Kidney Disease (CKD) In Adult Patients On Dialysis - Business Wire 03.27.12 | 02:03 pm
- Affymax® Reports Year End 2011 Financial Results - Business Wire 03.14.12 | 04:03 pm
- Affymax Announces Yearend 2011 Financial Results Teleconference And Webcast - Business Wire 03.07.12 | 04:03 pm
- Affymax To Receive $5 Million Milestone Payment For Acceptance Of European Marketing Authorization Application For Peginesatide - Business Wire 02.27.12 | 08:02 am
- Affymax Announces Upcoming Webcasts And Conference Participation - Business Wire 02.21.12 | 04:02 pm
- Affymax To Present At 14th Annual BIO CEO & Investor Conference - Business Wire 02.08.12 | 04:02 pm
Partner Headlines for AFFY
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 05.23.12 | 09:05 am
- The Definitive Biotech ETF Guide (IBB, XBI, FBT) - Benzinga 05.21.12 | 01:05 pm
- Amgen Beats but Maintains Outlook - Analyst Blog - Zacks 04.25.12 | 10:04 am
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Bio-Pharma Drug Approval Watch List: Final Results Plus One To Watch - Seeking Alpha 03.30.12 | 09:03 am
- Cramer's Lightning Round - Danaher Has Good Blood Lines (2/10/12) - Seeking Alpha 02.12.12 | 07:02 am
- Affymax Spiking Higher on Heavy Volume - Benzinga 12.27.11 | 01:12 pm
- 7 Stocks With Unusual Options Activity - Seeking Alpha 12.09.11 | 09:12 am
- Q3 Micro-Cap Biotech Picks By The World's Largest Fund Managers - Seeking Alpha 12.08.11 | 09:12 am
- Company News for December 6, 2011 - Corporate Summary - Zacks 12.06.11 | 10:12 am
